268 related articles for article (PubMed ID: 16759158)
21. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
[TBL] [Abstract][Full Text] [Related]
22. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
[TBL] [Abstract][Full Text] [Related]
23. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
24. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
25. Identification of five chromosomal regions involved in predisposition to melanoma by genome-wide scan in the MeLiM swine model.
Geffrotin C; Crechet F; Le Roy P; Le Chalony C; Leplat JJ; Iannuccelli N; Barbosa A; Renard C; Gruand J; Milan D; Horak V; Tricaud Y; Bouet S; Franck M; Frelat G; Vincent-Naulleau S
Int J Cancer; 2004 May; 110(1):39-50. PubMed ID: 15054867
[TBL] [Abstract][Full Text] [Related]
26. [Molecular biology of familial cases of human melanoma].
Kit OI; Vodolazhsky DL; Timoshkina NN; Przhedetsky YV; Khokhlova OV
Vopr Onkol; 2015; 61(6):889-97. PubMed ID: 26995975
[TBL] [Abstract][Full Text] [Related]
27. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients.
Council ML; Gardner JM; Helms C; Liu Y; Cornelius LA; Bowcock AM
Exp Dermatol; 2009 May; 18(5):485-7. PubMed ID: 19320745
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
[TBL] [Abstract][Full Text] [Related]
29. No Evidence for BRAF as a melanoma/nevus susceptibility gene.
Jackson S; Harland M; Turner F; Taylor C; Chambers PA; Randerson-Moor J; Swerdlow AJ; dos Santos Silva I; Beswick S; Bishop DT; Newton Bishop JA
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):913-8. PubMed ID: 15824163
[TBL] [Abstract][Full Text] [Related]
30. Melanoma genetics: an update on risk-associated genes.
Udayakumar D; Tsao H
Hematol Oncol Clin North Am; 2009 Jun; 23(3):415-29, vii. PubMed ID: 19464594
[TBL] [Abstract][Full Text] [Related]
31. Vitamin D receptor variants and the malignant melanoma risk: a population-based study.
Gapska P; Scott RJ; Serrano-Fernandez P; Mirecka A; Rassoud I; Górski B; Cybulski C; Huzarski T; Byrski T; Nagay L; Maleszka R; Sulikowski M; Lubinski J; Debniak T
Cancer Epidemiol; 2009 Aug; 33(2):103-7. PubMed ID: 19679055
[TBL] [Abstract][Full Text] [Related]
32. Management of familial melanoma.
Bishop JN; Harland M; Randerson-Moor J; Bishop DT
Lancet Oncol; 2007 Jan; 8(1):46-54. PubMed ID: 17196510
[TBL] [Abstract][Full Text] [Related]
33. The genetics of susceptibility to cutaneous melanoma.
Newton Bishop JA; Bishop DT
Drugs Today (Barc); 2005 Mar; 41(3):193-203. PubMed ID: 15883616
[TBL] [Abstract][Full Text] [Related]
34. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
35. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.
Goldstein AM; Landi MT; Tsang S; Fraser MC; Munroe DJ; Tucker MA
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2208-12. PubMed ID: 16172233
[TBL] [Abstract][Full Text] [Related]
36. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
[TBL] [Abstract][Full Text] [Related]
37. MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients.
Ghiorzo P; Bonelli L; Pastorino L; Bruno W; Barile M; Andreotti V; Nasti S; Battistuzzi L; Grosso M; Bianchi-Scarrà G; Queirolo P
Exp Dermatol; 2012 Sep; 21(9):718-20. PubMed ID: 22804906
[TBL] [Abstract][Full Text] [Related]
38. A review of inherited predisposition to melanoma.
Cannon-Albright LA; Kamb A; Skolnick M
Semin Oncol; 1996 Dec; 23(6):667-72. PubMed ID: 8970585
[TBL] [Abstract][Full Text] [Related]
39. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
[TBL] [Abstract][Full Text] [Related]
40. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
